TY - JOUR
T1 - Comparative proteomic profiles of meningioma subtypes
AU - Okamoto, Hiroaki
AU - Li, Jie
AU - Vortmeyer, Alexander O.
AU - Jaffe, Howard
AU - Lee, Youn Soo
AU - Gläsker, Sven
AU - Sohn, Tae Sung
AU - Zeng, Weifen
AU - Ikejiri, Barbara
AU - Proescholdt, Martin A.
AU - Mayer, Christina
AU - Weil, Robert J.
AU - Oldfield, Edward H.
AU - Zhuang, Zhengping
PY - 2006/10/15
Y1 - 2006/10/15
N2 - Meningiomas are classified into three groups (benign, atypical, and anaplastic) based on morphologic characteristics. Atypical meningiomas, which are WHO grade 2 tumors, and anaplastic meningiomas, which are WHO grade 3 tumors, exhibit an increased risk of recurrence and premature death compared with benign WHO grade 1 tumors. Although atypical and anaplastic meningiomas account for <10% of all of meningiomas, it can be difficult to distinguish them from benign meningiomas by morphologic criteria alone. We used selective tissue microdissection to examine 24 human meningiomas and did two-dimensional gel electrophoresis to determine protein expression patterns. Proteins expressed differentially by meningiomas of each WHO grade were identified and sequenced. Proteomic analysis revealed protein expression patterns unique to WHO grade 1, 2, and 3 meningiomas and identified 24 proteins that distinguish each subtype. Fifteen proteins showed significant changes in expression level between benign and atypical meningiomas, whereas nine distinguished atypical from anaplastic meningiomas. Differential protein expression was confirmed by Western blotting and immunohistochemistry. We established differential proteomic profiles that characterize and distinguish meningiomas of increasing grades. The proteins and proteomic profiles enhance understanding of the pathogenesis of meningiomas and have implications for diagnosis, prognosis, and treatment.
AB - Meningiomas are classified into three groups (benign, atypical, and anaplastic) based on morphologic characteristics. Atypical meningiomas, which are WHO grade 2 tumors, and anaplastic meningiomas, which are WHO grade 3 tumors, exhibit an increased risk of recurrence and premature death compared with benign WHO grade 1 tumors. Although atypical and anaplastic meningiomas account for <10% of all of meningiomas, it can be difficult to distinguish them from benign meningiomas by morphologic criteria alone. We used selective tissue microdissection to examine 24 human meningiomas and did two-dimensional gel electrophoresis to determine protein expression patterns. Proteins expressed differentially by meningiomas of each WHO grade were identified and sequenced. Proteomic analysis revealed protein expression patterns unique to WHO grade 1, 2, and 3 meningiomas and identified 24 proteins that distinguish each subtype. Fifteen proteins showed significant changes in expression level between benign and atypical meningiomas, whereas nine distinguished atypical from anaplastic meningiomas. Differential protein expression was confirmed by Western blotting and immunohistochemistry. We established differential proteomic profiles that characterize and distinguish meningiomas of increasing grades. The proteins and proteomic profiles enhance understanding of the pathogenesis of meningiomas and have implications for diagnosis, prognosis, and treatment.
UR - https://www.scopus.com/pages/publications/33750535006
U2 - 10.1158/0008-5472.CAN-06-0955
DO - 10.1158/0008-5472.CAN-06-0955
M3 - Article
C2 - 17047085
AN - SCOPUS:33750535006
SN - 0008-5472
VL - 66
SP - 10199
EP - 10204
JO - Cancer Research
JF - Cancer Research
IS - 20
ER -